This article is more than 5 years old. Information may no longer be current.
Glycemic control, fasting plasma glucose improved with once-weekly exenatide
Click Here to Manage Email Alerts
American Diabetes Association 68th Scientific Sessions
SAN FRANCISCO – An investigational formulation of once-weekly exenatide produced better improvements in HbA1c and fasting plasma glucose when compared with twice-daily exenatide, according to DURATION-1 trial findings released today.
DURATION-1 compared the efficacy of twice-daily exenatide (Byetta, Amylin), an FDA-approved incretin mimetic, with once-weekly exenatide, a long-acting release investigational formulation. The researchers randomly assigned 295 patients with type 2 diabetes to one of the two treatment arms for 30 weeks. The data were presented at the 68th Annual Scientific Sessions of the American Diabetes Association, held here.
“The DURATION-1 results suggested the significant, beneficial impact of continuous levels of exenatide once weekly on glycemic control, and, additionally, weight loss,” Donald J. Drucker, MD, director, Banting and Best Diabetes Centre, Toronto, and presenter of these data, said in a press release.
While patients in both treatment arms experienced improvements in HbA1c at 30 weeks, the changes were greater with once-weekly exenatide (1.9% vs. 1.5%). More than three-quarters, or 77%, of patients treated with once-weekly exenatide achieved the target HbA1c <7% compared with 61% of patients treated with twice-daily exenatide. The researchers also reported greater improvements in glycemic control among patients who entered the study with HbA1c >9% - 29% of once-weekly exenatide-treated patients achieved a target HbA1c <6.5% vs. 13% of twice-daily exenatide-treated patients.
Once-weekly exenatide was also associated with significant reductions in fasting plasma glucose (42.3 mg/dL vs. 25 mg/dL) and improvements in total cholesterol (11.9 mg/dL), LDL cholesterol (4.9 mg/dL), HDL cholesterol (0.9 mg/dL) and triglycerides (15%).
In addition, patients assigned to both formulations had an average weight loss of 8 lbs.
The most commonly reported adverse event was nausea; it was less frequent with once-weekly exenatide (26% vs. 35%). – by Katie Kalvaitis
For more information:
- Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly results in significantly greater improvements in glycemic control compared to exenatide twice daily in patients with type 2 diabetes. 107-OR. Presented at: American Diabetes Association 68th Scientific Sessions; June 6-10, 2008; San Francisco